AZ's Brilinta Patents 'Vulnerable' To Challenge In India
Executive Summary
An Indian court has lifted restraining orders against Micro Labs, Dr Reddy’s and Natco and held that they have made a “strong credible challenge” to the validity of AstraZeneca’s patents for Brilinta in the country. The UK firm has appealed the order.
You may also be interested in...
Natco Pivots To Emerging Markets To Drive Growth As Q1 Net Profit Slides
Indian company Natco said it is looking to emerging markets, including Brazil and China, to grow earnings as its first-quarter net profit dropped by a fifth in its financial first quarter.
AstraZeneca Seeks To Block Dr Reddy’s US Brilinta Rival
AstraZeneca has petitioned a US court to stop India’s Dr Reddy’s from launching a generic version of its blood clot-fighting drug Brilinta, accusing the Indian drugmaker of patent infringement.
AstraZeneca Seeks To Ward Off Brilinta Patent Infringer In India
An Indian court has blocked an alleged infringer of AstraZeneca's patent pertaining to Brilinta (ticagrelor), but the case, some experts claim, also brings to the fore certain controversial tactics at play in the legal arena as large firms pursue litigation to safeguard their intellectual property.